Liquid Biopsy Market : Distribution by Application, Target Disease Indication, Type of Circulating Biomarker, Type of Sample, Stage of Development, Type of Product, & Technique, Key Geographical Regions: Industry Trends & Global Forecasts, 2018-2035

Description

The global liquid biopsy market is valued at USD 5.4 billion in 2023 growing at a CAGR of 15.2% during the forecast period 2023-2035.

Cancer stands as the second most prevalent cause of mortality worldwide, presenting an escalating global health concern. Projections by the World Health Organization (WHO) estimate a staggering 16.3 million cancer-related fatalities by 2040. Among the spectrum of cancer types, breast cancer leads as the most commonly occurring globally, trailed by lung, colorectal, and prostate cancers. Statistical data from the Surveillance, Epidemiology, and End Results (SEER) program indicate an anticipated 18% lifetime diagnosis rate for women regarding breast cancer, with an estimated 297,790 new cases anticipated in 2023. To counteract this mounting burden, numerous cancer research institutions actively engage in pioneering methodologies and patient-centric strategies targeting early detection and treatment of cancer. Early identification of cancer constitutes a pivotal factor in bolstering treatment efficacy and augmenting patient survival rates. For decades, tissue biopsy has stood as the benchmark for cancer diagnosis. However, the drawbacks inherent in this invasive procedure-ranging from discomfort, pain to the risk of complications-have impeded its widespread adoption. Nonetheless, extensive exploration into liquid biopsy over recent years has propelled its acknowledgment as a viable diagnostic technique for cancer. The last decade, in particular, has witnessed remarkable advancements in liquid biopsy platforms, resulting in increased regulatory endorsements for minimally invasive blood-based tests. These products present an avenue for early cancer detection and patient monitoring, offering accessibility and minimal invasiveness. Leveraging blood samples or other bodily fluids like urine or plasma, these tests discern genetic mutations and various circulating biomarkers, encompassing circulating tumor DNA, cell-free DNA, and extracellular vesicles. These non-invasive assessments are revolutionizing cancer care, particularly for individuals in advanced cancer stages.

Key Market Segments:

Application

Early Cancer Diagnosis
Patient Monitoring
Recurrence Monitoring

Type of Target Disease Indication

Bladder Cancer
Breast Cancer
Colorectal Cancer
Gastric Cancer
Lung Cancer
Prostate cancer
Others

Type of Circulating Biomarker

Cell Free DNA
Cell Free RNA
Circulating Tumor DNA
Extracellular Vesicles
Other Circulating Biomarkers

Type of Sample

Blood / Plasma
Other Analytes

End User

Hospitals
Research Institutes
Others

Key Geographical Regions:

North America
Europe
Asia-Pacific
Rest of the World

Research Coverage:

The report studies the liquid biopsy market based on application, target disease indication, type of circulating biomarker, type of sample, end users, stage of development, type of product, type of technique, application area and key geographical regions
The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth
The report assesses the potential advantages and obstacles within the market for those involved and offers information on the competitive environment for top players in the market.
The report forecasts the revenue of market segments with respect to four major regions
A detailed outline of the research approach employed for studying the liquid biopsy market and non-invasive cancer diagnostics. This includes methodologies, assumptions, and quality control measures adopted to ensure the reliability and accuracy of findings.
Examination of historical trends, currency fluctuations, foreign exchange impacts, recessions, and inflation measurements that influence the overall liquid biopsy market.
Concise summary capturing key insights from the research, providing a high-level view of the current status of the liquid biopsy market and its anticipated evolution in the short, mid, and long terms.
Overview of cancer statistics, emphasizing the global disease burden, the significance of early cancer detection and screening, and insights into different types of circulating biomarkers based on their functionality. Additionally, exploration of emerging trends in intellectual property related to non-invasive cancer diagnostics, liquid biopsy costs, benefits, challenges, and their importance.
Emphasis on the necessity and significance of non-invasive cancer diagnostics, inclusive of various imaging techniques, screening assays, advanced diagnostic approaches, along with their respective advantages and disadvantages.
Detailed assessment of the liquid biopsy product market based on multiple parameters like development stage, product types (assay kits, devices, software/algorithms), sample types, techniques used, circulating biomarkers, target disease indications, applications, and players involved.
Tabulated profiles of leading liquid biopsy companies focusing on their establishment, workforce, headquarters, financial performance, product portfolio, recent developments, and future outlook.
Examination of recent collaborations within the liquid biopsy market, considering parameters such as partnership types, circulating biomarkers, target disease indications, most active players, and regional distributions.
In-depth analysis of funding and investments in liquid biopsy companies between 2016 and 2023, considering various parameters like funding types, target disease indications, application areas, geographic distribution, leading investors, and notable funding instances.
Detailed evaluation of liquid biopsy product competitiveness based on supplier strength, product attributes, company size, and technological advancements.
Comprehensive analysis of initiatives by major pharmaceutical companies, focusing on areas of interest, stages of development, product types, target indications, and application areas.
Review of historical acquisition activities since 2016, identifying potential acquisition targets within the industry.
Detailed insight into various non-invasive diagnostic tests, besides liquid biopsies, offered by different companies for cancer screening and early detection.
In-depth examination of growth factors, potential limitations, emerging opportunities, and existing challenges influencing the liquid biopsy market.

Key Benefits of Buying this Report:

The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
The report provides stakeholders with a pulse on the liquid bipsy market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Key Market Companies:

Amoy Diagnostics
ArcherDX
Biocartis
Cell Search
CellMax Life
Datar Cancer Genetics
DiaCarta, EONE-DIAGNOMICS
Exosome Diagnostics
GeneCast Biotechnology
Integrated DNA Technologies
Lucence
MDNA Life Sciences

Miltenyi Biotec
NeoGenomics
ONCODE Scientific
OncoDNA
QIAGEN
PANAGENE
Personal Genome Diagnostics
Predicin
ScreenCell
Tecan
Thermo Fisher Scientific

Product Code: RA100460

1. PREFACE

1.1. Chapter Overview
1.2. Project Objectives
1.3. Scope of the Report
1.4. Inclusions and Exclusions
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
- 2.7.1. Demographics
- 2.7.2. Economic Factors
- 2.7.3. Government Regulations
- 2.7.4. Supply Chain
- 2.7.5. COVID Impact / Related Factors
- 2.7.6. Market Access
- 2.7.7. Healthcare Policies
- 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

3.1. Chapter Overview
3.2. Market Dynamics
- 3.2.1. Time Period
  - 3.2.1.1. Historical Trends
  - 3.2.1.2. Current and Forecasted Estimates
- 3.2.2. Currency Coverage
  - 3.2.2.1. Overview of Major Currencies Affecting the Market
  - 3.2.2.2. Impact of Currency Fluctuations on the Industry
- 3.2.3. Foreign Exchange Impact
  - 3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
  - 3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
- 3.2.4. Recession
  - 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
  - 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
- 3.2.5. Inflation
  - 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
  - 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

5.1. Chapter Overview
5.2. Cancer Statistics and Burden of the Disease
5.3. Importance of Early Cancer Detection
5.4. Cancer Screening and Diagnosis
5.5 Conventional Invasive Cancer Diagnostic Tests
- 5.5.1. Biopsy
- 5.5.2. Fine Needle Aspiration Biopsy
- 5.5.3. Core Needle Aspiration Biopsy
- 5.5.4. Vacuum-Assisted Biopsy
- 5.5.5. Image Guided Biopsy
- 5.5.6. Sentinel Node Biopsy
- 5.5.7. Surgical Biopsy
- 5.5.8. Endoscopic Biopsy
- 5.5.9. Bone Marrow Biopsy
- 5.5.10. Endoscopy
5.6. Need for Non-Invasive Approaches
5.7. Liquid Biopsy: Diagnosing Circulating Biomarkers
- 5.7.1 Circulating Tumor Cells
- 5.7.2. Circulating Tumor DNA/ Cell Free DNA
- 5.7.3. Exosomes
5.8. Costs and Benefits Associated with Liquid Biopsy and Non-Invasive Tests
5.9. Latest Intellectual Property Trends in Non-Invasive Cancer Diagnostics
5.10. Challenges Associated with Non-Invasive Cancer Diagnostics
5.11. Future Perspectives

6. NON-INVASIVE CANCER SCREENING AND DIAGNOSIS

6.1. Chapter Overview
6.2. Diagnostic Imaging
- 6.2.1. Magnetic Resonance Imaging (MRI)
- 6.2.2. Mammography
- 6.2.3. Bone Scan
- 6.2.4. Computerized Tomography (CT) Scan
- 6.2.5. Integrated Positron Emission Tomography (PET)- CT Scan
- 6.2.6. Ultrasound
- 6.2.7. X-ray Radiography (Barium Enema)
6.3. Screening Assays
- 6.3.1. Circulating Tumor Marker Test
- 6.3.2. Digital Rectal Exam (DRE)
- 6.3.3. Fecal Occult Blood Test (FOBT)
- 6.3.4. Multigated Acquisition (MUGA) Scan
- 6.3.5. Papanicolaou Test and Human Papilloma Virus Test
6.4. Advanced Non-Invasive Approaches
- 6.4.1. Cytogenetic / Gene Expression Studies
- 6.4.2. Molecular Signature-based Non-Invasive Methods
- 6.4.3. Saliva-based Oral Cancer Diagnostics
- 6.4.4. Vital Staining
- 6.4.5. Optical Biopsy
- 6.4.6 Other Diagnostic Techniques

7. LIQUID BIOPSY: MARKET LANDSCAPE

7.1. Chapter Overview
7.2. Liquid Biopsy Products: Overall Market Landscape
- 7.2.1. Analysis by Stage of Development
- 7.2.2. Analysis by Type of Product
- 7.2.3. Analysis by Type of Sample
- 7.2.4. Analysis by Type of Technique
- 7.2.5. Analysis by Type of Circulating Biomarker
- 7.2.6. Analysis by Tumor
- 7.2.7. Analysis by Target Disease Indication
- 7.2.8. Analysis by Application
- 7.2.9. Analysis by Application Area
7.3. Liquid Biopsy Product Manufacturers
- 7.3.1. Analysis by Year of Establishment
- 7.3.2. Analysis by Company Size
- 7.3.3. Analysis by Location of Headquarters (Region)
- 7.3.3. Analysis by Location of Headquarters (Country)
- 7.3.4. Most Active Players: Analysis by Number of Liquid Biopsy Products
7.4. Liquid Biopsy Products: Other Liquid Biopsy Products, Kits and Consumables
7.5. Liquid Biopsy Products: Contract Service Providers

8. COMPANY PROFILES

8.1. Chapter Overview
- 8.2.1. Amoy Diagnostics
  - 8.2.1.1. Company Overview
  - 8.2.1.2. Product Portfolio
  - 8.2.1.3. Recent Developments and Future Outlook
- 8.2.2. ArcherDX
  - 8.2.2.1. Company Overview
  - 8.2.2.2 Product Portfolio
  - 8.2.2.3. Recent Developments and Future Outlook
- 8.2.3. DiaCarta
  - 8.2.3.1. Company Overview
  - 8.2.3.2. Product Portfolio
  - 8.2.3.3 Recent Developments and Future Outlook
- 8.2.4. Integrated DNA Technologies
  - 8.2.4.1. Company Overview
  - 8.2.4.2. Product Portfolio
  - 8.2.4.3. Recent Developments and Future Outlook
- 8.2.5 MDNA Life Sciences
  - 8.2.5.1. Company Overview
  - 8.2.5.2. Financial Information
  - 8.2.5.3 Product Portfolio
  - 8.2.5.4. Recent Developments and Future Outlook
- 8.2.6. NeoGenomics
  - 8.2.6.1. Company Overview
  - 8.2.6.2. Product Portfolio
  - 8.2.6.3. Recent Developments and Future Outlook
- 8.2.7. ONCODE Scientific
  - 8.2.7.1. Company Overview
  - 8.2.7.2. Product Portfolio
  - 8.2.7.3. Recent Developments and Future Outlook
- 8.2.8. QIAGEN
  - 8.2.8.1. Company Overview
  - 8.2.8.2. Financial Information
  - 8.2.8.3. Product Portfolio
  - 8.2.8.4. Recent Developments and Future Outlook
- 8.2.9. ScreenCell
  - 8.2.9.1. Company Overview
  - 8.2.9.2. Financial Information
  - 8.2.9.3. Product Portfolio
  - 8.2.9.4. Recent Developments and Future Outlook
- 8.2.10. Thermo Fisher Scientific
  - 8.2.10.1. Company Overview
  - 8.2.10.2. Financial Information
  - 8.2.10.3. Product Portfolio
  - 8.2.10.4. Recent Developments and Future Outlook
8.3. Other Leading Players in Liquid Biopsy Market
- 8.3.1. Biocartis
  - 8.3.1.1. Company Overview
  - 8.3.1.2. Product Portfolio
- 8.3.2. Cell Search
  - 8.3.2.1. Company Overview
  - 8.3.2.2. Product Portfolio
- 8.3.3. CellMax Life
  - 8.3.3.1. Company Overview
  - 8.3.3.2. Product Portfolio
- 8.3.4. Datar Cancer Genetics
  - 8.3.4.1. Company Overview
  - 8.3.4.2. Product Portfolio
- 8.3.5. EONE-DIAGNOMICS Genome Center
  - 8.3.5.1. Company Overview
  - 8.3.5.2. Product Portfolio
- 8.3.6. Exosome Diagnostics
  - 8.3.6.1. Company Overview
  - 8.3.6.2. Product Portfolio
- 8.3.7. GeneCast Biotechnology
  - 8.3.7.1. Company Overview
  - 8.3.7.2. Product Portfolio
- 8.3.8. Inivata
  - 8.3.8.1. Company Overview
  - 8.3.8.2. Product Portfolio
- 8.3.9. Lucence
  - 8.3.90.1. Company Overview
  - 8.3.9.2. Product Portfolio
- 8.3.10. Miltenyi Biotec
  - 8.3.10.1. Company Overview
  - 8.3.10.2. Product Portfolio
- 8.3.11. OncoDNA
  - 8.3.11.1. Company Overview
  - 8.3.11.2. Product Portfolio
- 8.3.12. PANAGENE
  - 8.3.12.1. Company Overview
  - 8.3.12.2. Product Portfolio
- 8.3.13. Personal Genome Diagnostics
  - 8.3.13.1. Company Overview
  - 8.3.13.2. Product Portfolio
- 8.3.14. Predicine
  - 8.3.14.1. Company Overview
  - 8.3.14.2. Product Portfolio
- 8.3.15. Tecan
  - 8.3.15.1. Company Overview
  - 8.3.15.2. Product Portfolio

9. PARTNERSHIPS AND COLLABORATIONS

9.1. Chapter Overview
9.2. Partnership Models
9.3. Liquid Biopsy: Partnerships and Collaborations
- 9.3.1. Analysis by Year of Partnership
- 9.3.2. Analysis by Type of Partnership
- 9.3.3. Analysis by Year and Type of Partnership
- 9.3.4. Analysis by Type of Partner
- 9.3.5. Analysis by Year of Partnership and Type of Partner
- 9.3.6. Analysis by Type of Partnership and Type of Partner
- 9.3.7. Analysis by Type of Circulating Biomarker
- 9.3.8. Analysis by Target Disease Indication
- 9.3.9. Most Active Players: Analysis by Number of Partnerships
- 9.3.10. Analysis by Geography
  - 9.3.10.1. Local and International Agreements
  - 9.3.10.2 Intercontinental and Intracontinental Agreements

10. FUNDING AND INVESTMENT ANALYSIS

10.1. Chapter Overview
10.2. Types of Funding
10.3. Liquid Biopsy: Funding and Investment Analysis
- 10.3.1. Analysis by Year of Investment
- 10.3.2. Analysis of Amount Invested by Year
- 10.3.3. Analysis by Type of Funding
- 10.3.4. Analysis of Amount Invested by Type of Funding
- 10.3.5. Analysis by Year and Type of Funding
- 10.3.6. Analysis by Type of Circulating Biomarker
- 10.3.7. Analysis by Target Disease Indication
- 10.3.8. Analysis by Application Area
- 10.3.9. Analysis by Geography
- 10.3.10. Most Active Players: Analysis by Number of Funding Instances
- 10.3.11. Most Active Players: Analysis by Amount Raised
- 10.3.12. Most Active Investors: Analysis by Number of Funding Instances

11. PRODUCT COMPETITIVENESS ANALYSIS

11.1. Chapter Overview
11.2. Methodology
11.3. Assumptions and Key Parameters
11.4. Liquid Biopsy: Product Competitiveness Analysis
- 11.4.1. Liquid Biopsy Assay Kits
  - 11.4.1.1. Products Offered by Players based in North America
  - 11.4.1.2. Products Offered by Players based in Europe
  - 11.4.1.3. Products Offered by Players based in Asia-Pacific
  - 11.4.1.4. Products Offered by Players based in Rest of the World
- 11.4.2. Liquid Biopsy Devices
  - 11.4.2.1. Products Offered by Players based in North America
  - 11.4.2.2. Products Offered by Players based in Europe and Asia-Pacific
- 11.4.3. Liquid Biopsy Software

12. BIG PHARMA INITIATIVES

12.1. Chapter Overview
12.2. Top Pharmaceutical Companies
- 12.2.1. Analysis by Type of Initiative
- 12.2.2. Analysis by Stage of Development
- 12.2.3. Analysis by Type of Product
- 12.2.4. Analysis by Type of Circulating Biomarker
- 12.2.5. Analysis by Target Disease Indication
- 12.2.6. Analysis by Application
- 12.2.7. Analysis by Application Area

13. KEY ACQUISITION TARGETS

13.1. Chapter Overview
13.2. Scope and Methodology
13.3. Scoring Criteria and Key Assumptions
13.4. Potential Acquisition Targets in North America
13.5. Potential Acquisition Targets in Europe
13.6. Potential Acquisition Targets in Asia-Pacific and Rest of the World
13.7. Concluding Remarks

14. OTHER NON-INVASIVE CANCER DIAGNOSTICS

14.1. Chapter Overview
14.2. Non-Blood-based Biomarker Detection Tests
14.3. FOBT and Fecal Immunochemical Tests (FIT)
14.4. Pigmented Lesion Assays
14.5. Stool DNA (sDNA)-based Tests
14.6. Volatile Organic Compound (VOC) Detection Tests
14.7. Other Non-Invasive Cancer Diagnostics: Market Landscape

15. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

15.1. Chapter Overview
15.2. Market Drivers
15.3. Market Restraints
15.4. Market Opportunities
15.5. Market Challenges
15.6. Conclusion

16. GLOBAL LIQUID BIOPSY MARKET

16.1. Chapter Overview
16.2. Key Assumptions and Methodology
16.3. Global Non-Invasive Cancer Diagnostics Market, (2023-2035)
16.4. Global Liquid Biopsy Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
- 16.4.1. Scenario Analysis
16.5. Key Market Segmentations
16.6. Dynamic Dashboard

17. LIQUID BIOPSY MARKET, BY APPLICATION

17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Early Cancer Diagnosis: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
17.4. Patient Monitoring: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
17.5. Recurrence Monitoring: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
17.6. Data Triangulation and Validation

18. LIQUID BIOPSY MARKET, BY TARGET DISEASE INDICATION

18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Bladder Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.4. Neurological Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.5. Breast Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.6. Cervical Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.7. Head and Neck Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.8. Leukemia: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.9. Liver Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.10. Lung Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.11. Melanoma: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.12. Nasopharyngeal Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.13. Oesophagus Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.14. Ovarian Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.15. Pancreatic Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.16. Prostate Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.17. Sarcoma: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.18. Stomach Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.19. Thyroid Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.20. Data Triangulation and Validation

19. LIQUID BIOPSY MARKET, BY TYPE OF CIRCULATING BIOMARKER

19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Cell-Free DNA: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
19.4. Circulating Tumor DNA: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
19.5. Extracellular Vesicles: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
19.6. Other Circulating Biomarkers: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
19.7. Data Triangulation and Validation

20. LIQUID BIOPSY MARKET, BY TYPE OF SAMPLE

20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Blood / Plasma Samples: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
20.4. Other Samples: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
20.5. Data Triangulation and Validation

21. LIQUID BIOPSY MARKET, BY TYPE OF END-USER

21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Hospitals: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
21.4. Research Institutes: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
21.5. Other End-users: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
21.6. Data Triangulation and Validation

22. LIQUID BIOPSY MARKET, BY KEY GEOGRAPHICAL REGIONS

22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. North America: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
22.4. Europe: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
22.5. Asia-Pacific and Rest of the World: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
22.6. Data Triangulation and Validation

23. SURVEY INSIGHTS

23.1. Chapter Overview
23.2. Company Specifics of Respondents
23.3. Analysis by Seniority Level of Respondents
23.4. Analysis by Type of Product Portfolio
23.5. Analysis by Type of Products / Services Offered
23.6. Analysis by Stage of Development of Product
23.7. Analysis by Application Area
23.8. Analysis by Likely Market Size

24. CONCLUSION

25. EXECUTIVE INSIGHTS

25.1. Chapter Overview
25.2. Foundation for the National Institutes of Health
- 25.2.1. Company Snapshot
- 25.2.2. Interview Transcript
25.3. Bahia Software
- 25.3.1. Company Snapshot
- 25.3.2. Interview Transcript
25.4. Genostics
- 25.4.1. Company Snapshot
- 25.4.2. Interview Transcript
25.5. Oncophenomics
- 25.5.1. Company Snapshot
- 25.5.2. Interview Transcript
25.6. Minomic International
- 25.6.1. Company Snapshot
- 25.6.2. Interview Transcript
25.7. IVDiagnostics
- 25.7.1. Company Snapshot
- 25.7.2. Interview Transcript
25.8. Tymora Analytical Operations
- 25.8.1. Company Snapshot
- 25.8.2. Interview Transcript
25.9. ProXeom
- 25.9.1. Company Snapshot
- 25.9.2. Interview Transcript
25.10. MiNDERA
- 25.10.1. Company Snapshot
- 25.10.2. Interview Transcript
25.11. Resolution Bioscience
- 25.11.1. Company Snapshot
- 25.11.2. Interview Transcript
25.12. Nanostics
- 25.12.1. Company Snapshot
- 25.12.2. Interview Transcript
25.13. DermTech
- 25.13.1. Company Snapshot
- 25.13.2. Interview Transcript
25.14. iCellate Medical
- 25.14.1. Company Snapshot
- 25.14.2. Interview Transcript
25.15. VolitionRx
- 25.15.1. Company Snapshot
- 25.15.2. Interview Transcript
25.16. OncoDNA
- 25.16.1. Company Snapshot
- 25.16.2. Interview Transcript
25.17. LCM Genect
- 25.17.1. Company Snapshot
- 25.17.2. Interview Transcript
25.18. Sienna Cancer Diagnostics
- 25.18.1. Company Snapshot
- 25.18.2. Interview Transcript